Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples
| Autor: | David Petroff, Olaf Bätz, Katrin Jedrysiak, J. Kramer, Johannes Wiegand, Thomas Berg |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty business.industry Liver fibrosis Fatty liver Gastroenterology Elevated liver enzymes Disease Primary care medicine.disease Secondary care 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Fibrosis Internal medicine medicine Etiology 030211 gastroenterology & hepatology business |
| Zdroj: | Gut. 70:219-221 |
| ISSN: | 1468-3288 0017-5749 |
| Popis: | We read with interest the recent article by Newsome et al which provides guidelines for general practitioners on the management of abnormal liver blood tests based on the clinical recognition pattern of elevated liver enzymes and recommendations on non-invasive laboratory based liver fibrosis scores such as Fibrosis-4 (FIB-4) to exclude advanced fibrosis.1 Patients with low FIB-4 values should be managed in primary care, those with intermediate test results receive further diagnostics by an enhanced liver fibrosis test or ultrasound based elastography methods while those with high FIB-4 score are directly referred to secondary care. Newsome’s recommendations are especially relevant for non-alcoholic fatty liver disease (NAFLD), the most common aetiology of elevated liver enzymes in the primary care setting in the Western world.2 In NAFLD, the key predictor for liver related outcome and mortality is liver fibrosis.3 4 In Germany by the year 2030, 17 million NAFLD patients will present without fibrosis, but … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|